Marshall Wace LLP is an employee-owned hedge fund manager based in London, United Kingdom, with additional offices in New York and Hong Kong. Founded in 1997, the firm specializes in global long/short equity investments and manages a variety of hedge funds and equity mutual funds for its clients. Marshall Wace employs a dual approach to asset management, integrating traditional fundamental analysis with proprietary systematic strategies, including its innovative MW TOPS alpha capture strategy. The firm focuses on delivering risk-adjusted returns by investing in public equity markets worldwide, as well as in alternative investment markets. Its diverse investment solutions cater to a range of sectors, including financial services, manufacturing, financial technology, and e-commerce.
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.
Attovia Therapeutics
Series B in 2024
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.